Premium
Cytolytic T‐cell responses of cancer patients vaccinated with a MAGE antigen
Author(s) -
Coulie Pierre G.,
Karanikas Vaios,
Lurquin Christophe,
Colau Didier,
Connerotte Thierry,
Hanagiri Takeshi,
Van Pel Aline,
Lucas Sophie,
Godelaine Danièle,
Lonchay Christophe,
Marchand Marie,
Van Baren Nicolas,
Boon Thierry
Publication year - 2002
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1034/j.1600-065x.2002.18804.x
Subject(s) - antigen , biology , immunology , t cell , cancer immunotherapy , cytolysis , virology , t lymphocyte , immunotherapy , cytotoxic t cell , ctl* , cancer research , immune system , genetics , cd8 , in vitro
Summary: ‘Cancer‐germline’ genes such as the MAGE gene family are expressed in many tumors and in male germline cells but not in normal tissues. They encode shared tumor‐specific antigens, which have been used in therapeutic vaccination trials of metastatic melanoma patients. To establish whether there is a correlation between tumoral regressions and T‐cell responses against the vaccine antigen, we evaluated the responses of patients vaccinated with a MAGE‐3 antigenic peptide or a recombinant virus coding for the peptide. Blood lymphocytes were stimulated with antigenic peptide followed by detection with tetramer, T‐cell cloning, and TCR analysis. In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE‐3 peptide.